Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE164551

Dataset summary for GSE164551

Datast information	Dataset	GSE164551
	PMID	33558511
	Raw data ID/link	https://doi.org/10.7910/DVN/1RKYQ8
	Organism	Homo sapiens
	Source	patients
	Tissue	Bone marrow aspirate
	Cancer type level1	Multiple myeloma
	Cancer type level2	Refractory multiple myeloma (MM)
	Regimen	CAR-T
	Drug type	Immunotherapy
	Sample size	resistant 1, sensitive 1
	Cell number	7736
	Extract protocol	10x genomics
	Data processing	CellRanger 3.1.0
	Public date	Public on Jan 11, 2021
	Description	This dataset has 1 patient with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE164551

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"CAR-T" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

resistant vs. sensitive

Dot plot of significant ligand-receptor pairs in the resistant group	Dot plot of significant ligand-receptor pairs in the sensitive group

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
RAF1	ENSG00000132155	0.258652	5.92e-08	9.34e-04	0.394	0.298	Mono/Macro	NA
POLR2J3.1	NA	0.257958	2.05e-10	3.23e-06	0.329	0.211	Mono/Macro	NA
COL4A3BP	NA	0.257608	1.94e-09	3.06e-05	0.375	0.265	Mono/Macro	NA
MKLN1	ENSG00000128585	0.255331	2.10e-21	3.31e-17	0.255	0.104	Mono/Macro	NA
VAMP2	ENSG00000220205	0.254169	2.08e-10	3.28e-06	0.374	0.256	Mono/Macro	NA
PDK1	ENSG00000152256	0.25399	1.32e-09	2.08e-05	0.258	0.157	Mono/Macro	NA
TSC22D4	ENSG00000166925	0.251425	7.80e-20	1.23e-15	0.29	0.134	Mono/Macro	NA
TBL1XR1	ENSG00000177565	0.251218	9.97e-12	1.57e-07	0.253	0.142	Mono/Macro	NA
SWAP70	ENSG00000133789	0.250327	5.78e-18	9.12e-14	0.294	0.143	Mono/Macro	NA
COX5B	ENSG00000135940	-0.25149	1.20e-12	1.90e-08	0.361	0.527	Mono/Macro	NA
KAT6A	ENSG00000083168	-0.252146	5.67e-14	8.94e-10	0.169	0.332	Mono/Macro	NA
KLF10	ENSG00000155090	-0.25254	1.89e-13	2.98e-09	0.286	0.466	Mono/Macro	NA
MYH9	ENSG00000100345	-0.252771	2.04e-17	3.21e-13	0.271	0.486	Mono/Macro	NA
CORO1C	ENSG00000110880	-0.253602	2.62e-15	4.13e-11	0.19	0.371	Mono/Macro	NA
LAMTOR1	ENSG00000149357	-0.25387	1.04e-14	1.64e-10	0.214	0.39	Mono/Macro	NA
SDC4	ENSG00000124145	-0.253909	2.96e-16	4.66e-12	0.113	0.281	Mono/Macro	NA
ADM	ENSG00000148926	-0.254145	1.13e-13	1.78e-09	0.188	0.354	Mono/Macro	NA
NDUFS5	ENSG00000168653	-0.254251	1.72e-12	2.71e-08	0.325	0.494	Mono/Macro	NA
DAD1	ENSG00000129562	-0.254535	8.73e-18	1.38e-13	0.102	0.277	Mono/Macro	NA
PHPT1	ENSG00000054148	-0.255193	1.26e-17	1.99e-13	0.119	0.297	Mono/Macro	NA
RIOK3	ENSG00000101782	-0.255416	7.63e-14	1.20e-09	0.431	0.622	Mono/Macro	NA
TYROBP	ENSG00000011600	-0.255959	3.29e-12	5.18e-08	0.654	0.863	Mono/Macro	NA
SLC2A3	ENSG00000059804	-0.255979	1.81e-26	2.86e-22	0.743	0.938	Mono/Macro	NA
NCOR2	ENSG00000196498	-0.256401	5.90e-13	9.30e-09	0.221	0.382	Mono/Macro	NA
ATP5F1E	ENSG00000124172	-0.257275	6.99e-10	1.10e-05	0.766	0.818	Mono/Macro	NA
TRAPPC1	ENSG00000170043	-0.258041	1.08e-14	1.70e-10	0.223	0.397	Mono/Macro	NA
UBL5	ENSG00000198258	-0.258791	6.66e-14	1.05e-09	0.257	0.428	Mono/Macro	NA
TES	ENSG00000135269	-0.260809	2.81e-16	4.43e-12	0.203	0.393	Mono/Macro	NA
MOB3A	ENSG00000172081	-0.261478	2.43e-14	3.84e-10	0.271	0.449	Mono/Macro	NA
NUCB1	ENSG00000104805	-0.262123	4.82e-15	7.60e-11	0.204	0.382	Mono/Macro	NA
PET100	ENSG00000229833	-0.263222	3.91e-13	6.16e-09	0.342	0.513	Mono/Macro	NA
HNRNPA3	ENSG00000170144	-0.264482	1.58e-15	2.49e-11	0.442	0.638	Mono/Macro	NA
EDF1	ENSG00000107223	-0.26462	1.56e-14	2.45e-10	0.323	0.503	Mono/Macro	NA
TUBB6	ENSG00000176014	-0.265564	1.57e-19	2.48e-15	0.087	0.271	Mono/Macro	NA
PPP4R3A	ENSG00000100796	-0.26557	1.24e-13	1.96e-09	0.266	0.441	Mono/Macro	NA
FCAR	ENSG00000276858	-0.26617	8.55e-15	1.35e-10	0.485	0.7	Mono/Macro	NA
LRRC8C	ENSG00000171488	-0.266211	2.49e-18	3.93e-14	0.097	0.275	Mono/Macro	NA
PPIB	ENSG00000166794	-0.266487	4.10e-15	6.47e-11	0.262	0.458	Mono/Macro	NA
PTP4A1	ENSG00000112245	-0.26697	4.54e-16	7.15e-12	0.193	0.379	Mono/Macro	NA
CD99	ENSG00000002586	-0.266973	1.27e-13	2.00e-09	0.401	0.586	Mono/Macro	NA
CIB1	ENSG00000185043	-0.269048	9.87e-16	1.56e-11	0.236	0.423	Mono/Macro	NA
GPX4	ENSG00000167468	-0.269206	9.26e-14	1.46e-09	0.467	0.647	Mono/Macro	NA
BRI3	ENSG00000164713	-0.269243	2.34e-13	3.68e-09	0.574	0.78	Mono/Macro	NA
IL1RAP	ENSG00000196083	-0.269407	7.06e-18	1.11e-13	0.086	0.257	Mono/Macro	NA
COX6C	ENSG00000164919	-0.270443	1.87e-13	2.94e-09	0.368	0.554	Mono/Macro	NA
PKM	ENSG00000067225	-0.270655	2.19e-11	3.44e-07	0.487	0.655	Mono/Macro	NA
RPL35	ENSG00000136942	-0.271447	9.43e-14	1.49e-09	0.818	0.882	Mono/Macro	NA
RPL23	ENSG00000125691	-0.271635	1.20e-13	1.89e-09	0.758	0.856	Mono/Macro	NA
MYL12A	ENSG00000101608	-0.271874	1.94e-14	3.06e-10	0.34	0.53	Mono/Macro	NA
NDUFB2	ENSG00000090266	-0.273389	2.52e-16	3.97e-12	0.139	0.312	Mono/Macro	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	5.90e-02	2.90e-01	12	781	2	23467	Malignant cells	EGR1,CXCL8
Epigenetic Alteration of DNA, RNA or Protein	2.10e-01	5.20e-01	12	455	1	23467	Malignant cells	CXCL8
Aberration of the Drug's Therapeutic Target	1.00e+00	1.00e+00	12	90	0	23467	Malignant cells
Drug Inactivation by Structure Modification	1.00e+00	1.00e+00	12	27	0	23467	Malignant cells
Irregularity in Drug Uptake and Drug Efflux	1.00e+00	1.00e+00	12	37	0	23467	Malignant cells

Enrichment results for 1 known drug resistance mechanisms in TME cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	3	186	0	23467	B cells	NA
Regulation by the Disease Microenvironment	6.60e-03	6.60e-03	148	186	5	23467	CD4+ T cells	BRAF,TGFB1,SOCS3,VIM,ZEB1
Regulation by the Disease Microenvironment	1.80e-01	1.80e-01	276	186	4	23467	CD8+ T cells	NFKB1,TGFB1,CXCR4,VIM
Regulation by the Disease Microenvironment	5.10e-01	5.10e-01	467	186	4	23467	Erythrocytes	BCL2L1,MTDH,HNRNPA2B1,MALAT1
Regulation by the Disease Microenvironment	9.20e-03	9.20e-03	524	186	10	23467	Mono_Macro	BRAF,CTNNB1,TGFB1,VEGFA,ZEB2,IL1B,HNRNPA2B1,SOCS3,VIM,MALAT1
Regulation by the Disease Microenvironment	4.80e-01	4.80e-01	81	186	1	23467	NK cells	VIM

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group
This dataset does not contain malignant cells, nor does it predict any miRNA that corresponds to the top10 DEGs.

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	transfac_pro__M02848	4.05	0.193	EGR1 (inferredBy_Orthology).	CD4+ T cells
	taipale_tf_pairs__ETV5_HES7_NNCACGTGNNNNCCGGAANN_CAP	4.02	0.192	ETV5; HES7 (directAnnotation).	CD4+ T cells
	transfac_pro__M07475	3.81	0.185	TBX5 (inferredBy_Orthology).	CD4+ T cells
	cisbp__M00775	3.79	0.184	ZBTB1 (inferredBy_Orthology).	CD4+ T cells
	metacluster_84.2	3.76	0.183	RARA (directAnnotation).	CD4+ T cells
	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	3.74	0.182	E2F1; ELK1 (directAnnotation).	CD4+ T cells
	metacluster_141.5	3.71	0.181	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).	CD4+ T cells
	jaspar__MA1650.1	3.68	0.18	ZBTB14 (directAnnotation).	CD4+ T cells
	transfac_pro__M02090	3.62	0.178	E2F4 (directAnnotation).	CD4+ T cells
	transfac_pro__M08005	3.56	0.176	TCFL5 (inferredBy_Orthology).	CD4+ T cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	transfac_pro__M01252	7.71	0.61	E2F6 (directAnnotation).	B cells
	tfdimers__MD00310	7.02	0.558	IKZF1; OTX1; OTX2 (directAnnotation).	B cells
	metacluster_76.1	6.65	0.53	ZNF345; ZNF345 (directAnnotation). MYB; MYBL1 (inferredBy_Orthology).	B cells
	metacluster_156.2	6.56	0.523	ATF3; ATF4; ATF4; ATF4; ATF4; ATF4; ATF4; CEBPG; CEBPG; DDIT3; MYC (directAnnotation). ATF4; ATF4; ATF4; CEBPG; DDIT3 (inferredBy_Orthology).	B cells
	transfac_pro__M05531	6.5	0.518	IKZF5 (inferredBy_Orthology).	B cells
	tfdimers__MD00103	6.44	0.514	ZNF333 (directAnnotation).	B cells
	cisbp__M00838	6.02	0.482	FOXP1 (directAnnotation).	B cells
	metacluster_130.1	5.99	0.48	ZNF713; ZNF713 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).	B cells
	metacluster_139.9	5.89	0.473	TFE3 (inferredBy_Orthology).	B cells
	tfdimers__MD00298	5.88	0.471	CEBPA; CEBPB; CEBPD; CEBPE; CEBPG; FOXL1 (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ZEB1	tfdimers__MD00527	up	CD4+ T cells	NA
MECP2	metacluster_135.10	up	CD8+ T cells	NA
E2F4	metacluster_45.6	down	Erythrocytes	NA
KLF13	hocomoco__KLF13_HUMAN.H11MO.0.D	down	Erythrocytes	NA
YBX1	metacluster_79.33	down	Erythrocytes	NA
BACH1	metacluster_22.37	up	Mono/Macro	NA
BACH1	metacluster_157.2	up	Mono/Macro	NA
BACH1	metacluster_30.4	up	Mono/Macro	NA
EGR1	cisbp__M01864	up	Mono/Macro	NA
EGR1	metacluster_131.7	up	Mono/Macro	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."